HomeInvestor Relations

Investor Relations

Company Profile

TOT BIOPAHRM International Company Limited dedicate to developing and commercializing innovative oncology drugs and therapies. Our mission is to build a leading brand name of oncology treatments trusted by patients and their families as well as medical professionals in China.

TOT BIOPHARM makes full use of open technology platforms and commercial production capabilities to speed up the development of “one stop, one base” CDMO/CMO business. We are able to provide our clients with “one stop” CDMO/CMO solutions spanning R&D, process development, clinical trials, registration and filing for approval as well as commercial production, thereby satisfying the diversified demand for products such as ADC drugs, mAb drugs and chemical drugs.

 

TOT BIOPHARM (Stock Code: 1875.HK) was successfully listed on the Main Board of Stock Exchange of Hong Kong Limited on 8 Nov 2019, which marks an important step towards accessing the international capital markets.

Registered Office
5/F, Manulife Place,348 Kwun Tong Road,Kowloon, Hong Kong
Legal Advisers
Sullivan & Cromwell (Hong Kong) LLP
Headquarters and Principal Place of Business in the PRC
120 Changyang Street, Suzhou Industrial Park, Suzhou, the PRC
Auditor
PricewaterhouseCoopers
Joint Company Secretaries
Mr. Chen, Yifan (陳一帆先生) Mr. Lui, Wing Yat Christopher (呂穎一先生)
Company Website
www.totbiopharm.com.cn
Authorized Representatives
Dr. Liu, Jun (刘军博士) Mr. Lui, Wing Yat Christopher (呂穎一先生)
Stock Code
1875.HK